Michel Sadelain, one of the fathers of CAR-T, promising cancer therapies: "They are living medicines that multiply inside the patient’s body."

The cells that are trained to kill blood tumors will have a more advanced version that obtains good results in the laboratory against pancreatic, ovarian and kidney cancers. “After designing and making them work, the challenge is their accessibility” Read

Source